ArticleClinical and translational science2025
Linkage Between Hemoglobin to High Density Lipoprotein-Cholesterol Ratio and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationally Representative Study.
Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) demands a better understanding of its risk factors. This study aimed to explore the relationship between the hemoglobin to high density lipoprotein-cholesterol ratio (HHR) and MASLD. Data from 3121 participants sourced from the National Health and Nutrition Examination Survey (NHANES) were analyzed. Weighted logistic regression models were constructed to evaluate the associations between HHR and MASLD. Subgroup analyses were conducted to probe potential heterogeneity, and sensitivity analyses, through redefining the CAP cut-off for hepatic steatosis, were employed to affirm the robustness of the observed associations. Increased HHR was independently associated with a higher risk of MASLD. Notably, this association was pronounced among smokers. While a preliminary positive correlation between HHR and liver fibrosis in MASLD patients was noted, it dissipated upon full adjustment. Sensitivity analysis confirmed the stability of the association between HHR and MASLD. Our study reveals a significant positive correlation between HHR and MASLD, with smoking status emerging as a modulatory factor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.